Evaluating the addition of oxaliplatin to single agent fluoropyrimidine in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis

References

• Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst. 2001;93:583–596.
   PubMed Web of Science ®Google Scholar
• Wibe A, Eriksen MT, Syse A, et al. Total mesorectal excision for rectal cancer–what can be achieved by a national audit? Colorectal Dis. 2003;5:471–477.
   PubMedGoogle Scholar
• Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–1123.
   PubMed Web of Science ®Google Scholar
• Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620–4625.
   PubMed Web of Science ®Google Scholar
• Resende HM, Jacob LFP, Quinellato LV, et al. Combination chemotherapy versus single-agent chemotherapy during preoperative chemoradiation for resectable rectal cancer. Cochrane Database Syst Rev. 2015. DOI: 10.1002/14651858.CD008531.pub2.
   PubMed Web of Science ®Google Scholar
• De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–2947.
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–3116.
   PubMed Web of Science ®Google Scholar
• Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465–1471.
   PubMed Web of Science ®Google Scholar
• Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696–2704.
   PubMed Web of Science ®Google Scholar
• Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29:2773–2780.
   PubMed Web of Science ®Google Scholar
• Hospers GA, Punt CJ, Tesselaar ME, et al. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. Phase I-II Multicenter Study Dutch Colorectal Cancer Group Annals Surgical Oncology. 2007;14:2773–2779.
   Google Scholar
• Rodel C, Grabenbauer GG, Papadopoulos T, et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol. 2003;21:3098–3104.
   PubMed Web of Science ®Google Scholar
• Ryan DP, Niedzwiecki D, Hollis D, et al. Phase I/II Study of Preoperative Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy in Patients With Locally Advanced Rectal Cancer: cancer and Leukemia Group B 89901. J Clin Oncol. 2006;24:2557–2562.
   PubMed Web of Science ®Google Scholar
• Nimeiri H, Feng Y, Catalano P, et al. Intergroup randomized phase III study of postoperative irinotecan, 5-fluorouracil, and leucovorin versus oxaliplatin, 5-fluorouracil, and leucovorin versus 5-fluorouracil and leucovorin for patients with stage II or III rectal cancer receiving either preoperative radiation and 5-fluorouracil or postoperative radiation and 5-fluorouracil: ECOG E3201—an updated survival analysis. J Clin Oncol. 2013;31:e14711.
   Web of Science ®Google Scholar
• Schmoll HJ, Haustermans K, Price T, et al. O-0017Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: disease free survival at interim analysis. Ann Oncol. 2014;25:ii111–ii2.
   Google Scholar
• Dudinik R, Rutten H, Martijnse I Combined oxaliplatin and capecitabine is the most effective neoadjuvant treatment for locally advanced rectal cancer. Annals of Surgical Oncology Conference Abstract. 2011;18:S15.
   Google Scholar
• Jin J, Feng Y, Li Y. Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase 3 trial. Eur J Cancer Conf Abstract. 2015;51:S350.
   Web of Science ®Google Scholar
• Valentini V, De Paoli A, Barba M. Capecitabine based preoperative chemo-RT in rectal cancer intensified by RT or oxaliplatin: the INTERACT trial. ESTRO Proffered Papers. 2014;33:OC–0494.
   Google Scholar
• Caravatta L, Picardi V, Tambaro R, et al. Neoadjuvant accelerated concomitant boost radiotherapy and multidrug chemotherapy in locally advanced rectal cancer: a dose-escalation study. Am J Clin Oncol. 2012;35:424–431.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d928.
   Google Scholar
• O’Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;32:1927–1934.
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Yothers G, O’connell MJ, et al. Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J Natl Cancer Inst. 2015; 107.
   Google Scholar
• Saha A, Ghosh SK, Roy C, et al. A randomized controlled pilot study to compare capecitabine-oxaliplatin with 5-FU-leucovorin as neoadjuvant concurrent chemoradiation in locally advanced adenocarcinoma of rectum. J Cancer Res Ther. 2015;11:88–93.
   PubMed Web of Science ®Google Scholar
• Gerard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28:1638–1644.
   PubMed Web of Science ®Google Scholar
• Gerard JP, Azria D, Gourgou-Bourgade S, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30:4558–4565.
   PubMed Web of Science ®Google Scholar
• Rodel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. The Lancet Oncology. 2012;13:679–687.
   PubMed Web of Science ®Google Scholar
• Rodel C, Graeven U, Fietkau R, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. 2015;16:979–989.
   PubMed Web of Science ®Google Scholar
• Hong YS, Nam BH, Kim KP, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. The Lancet Oncology. 2014;15:1245–1253.
   PubMed Web of Science ®Google Scholar
• Jiao D, Zhang R, Gong Z, et al. Fluorouracil-based preoperative chemoradiotherapy with or without oxaliplatin for stage II/III rectal cancer: a 3-year follow-up study. Chin J Cancer Res. 2015;27:588–596.
   PubMed Web of Science ®Google Scholar
• Francois E, Gourgou-Bourgade S, Azria D, et al. ACCORD12/0405-Prodige 2 phase III trial neoadjuvant treatment in rectal cancer: results after 5 years of follow-up. J Clin Oncol. 2016;34:suppl 4S abstr 490.
   Google Scholar
• Gerard JP, Chamorey E, Gourgou-Bourgade S, et al. Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial. Radiother Oncol. 2015;115:246–252, *
   PubMed Web of Science ®Google Scholar
• Park IJ, You YN, Agarwal A, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012;30:1770–1776.
   PubMed Web of Science ®Google Scholar
• Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835–844.
   PubMed Web of Science ®Google Scholar
• Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol. 2006;24:668–674.
   PubMed Web of Science ®Google Scholar
• Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014;32:513–518.
   PubMed Web of Science ®Google Scholar
• Breugom AJ, Swets M, Bosset J-F, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16:200–207.
   PubMed Web of Science ®Google Scholar
• Bujko K, Glimelius B, Valentini V, et al. Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: a meta-analysis of randomized trials comparing surgery +/- a fluoropyrimidine and surgery + a fluoropyrimidine +/- oxaliplatin. Eur Jl Surgil Oncol. 2015;41:713–723.
   PubMed Web of Science ®Google Scholar
• An X, Lin X, Wang FH, et al. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis. Eur J Can. 2013;49:843–851.
   PubMed Web of Science ®Google Scholar